DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20184432

A comparative study between first generation and second generation antipsychotics over the development of metabolic syndrome in persons with first episode drug naive schizophrenia

Pakkiyalakshmi N., Suriyamoorthi M., Ravishankar J.

Abstract


Background: Antipsychotic treatment for schizophrenia is prone for drug side effects. Both typical and atypical antipsychotics are prone for metabolic derangements. The aim of this study was to compare the emergence of metabolic syndrome with haloperidol and risperidone in drug naïve first episode schizophrenics.

Methods: This was a prospective observational study conducted at the Institute of Mental health, Chennai, India from April 1, 2011 to November 15, 2011. 24 patients received haloperidol and 29 patients received risperidone and followed up for 6 months, after obtaining informed consent. PANSS score, AHA criteria for metabolic syndrome, plasma glucose, waist-hip ratio, body mass index and lipid profile were recorded at every two months interval.

Results: PANSS score showed a decrease in both groups, systolic blood pressure showed an increase with Haloperidol and an initial decrease with risperidone while diastolic blood pressure increased with haloperidol. Weight gain, increase in waist circumference and hip circumference, rise in triglyceride levels and fall in HDL cholesterol were equally observed in both groups. Increase in plasma glucose was seen more with risperidone (93.1%). 18.86%  (n = 10) developed metabolic syndrome at the end of 6months with no difference in emergence between both groups.

Conclusions: Risperidone may be considered equivalent to haloperidol in efficacy and with minimal changes in metabolic profile. Blood pressure lowering effect of risperidone is more marked in earlier months warranting patient education. Stringent guidelines are needed during antipsychotic treatment to prevent cardiovascular and cerebrovascular morbidity and mortality.


Keywords


Blood pressure, Haloperidol, Metabolic syndrome, Risperidone

Full Text:

PDF

References


Margolese HC, Chouinard G, kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. part 2: incidence and management strategies in patients with schizophrenia. Canadian J Psychiatry. 2005;50(11):703-14.

Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: A systematic review. Schizophrenia Res. 2004;71(2-3):195-212.

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(111):1686-96.

Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A, et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry. 2003;64(12):1436-9.

Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizo Res. 2004;70(1):1-17.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 2002.

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005 Oct 25;112(17):2735-52.

Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert review of neurotherapeutics. 2010;10(7):1175-1200.

Lane HY, Chang YC, Cheng YC, Liu GC, Lin XR, Chang WH. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry. 2003;64(3):316-20.

Zhang S, Lan G. Prospective 8-week trial on the effect of olanzapine, quetiapine, and aripiprazole on blood glucose and lipids among individuals with first-onset schizophrenia. Shanghai Archives Psychiatry. 2014;26(6):339-46.

Chaudhry HR, Arshad N, Niaz S, Suleman T, Mufti KA. Comparison of Risperidone, olanzapine and quetiapine: effects on body weight, serum blood glucose and prolactin. International Psychiatry. 2008;5(3):71-3.

Hempel RJ, Tulen JH, Van Beveran NJ, Roder CH, Hengeveld MW. Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia. J Psychopharmacol. 2009;23(6):697-707.

Choure BK, Gosavi D, Nanotkar S. Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: A prospective open label observational study. Indian J Pharmacol. 2014;46(5):493-7.

Kalaimathi B, Rahamathulla MI, Lakshmi MM, Gnanadurai AWJ, Jothi SR, Priyadharshini R, et al. Metabolic side effects of Haloperidol and Risperidone-A six months follow up study. J Evi Based Med Health. 2017;4(25):1463-7.